News

We're proud to share our 2025 Impact Report, highlighting a year of meaningful growth in awareness, connection, and navigation for patients and caregivers facing advanced abdominal cancers. This report reflects the collective impact of our community working together to help more people access the information and specialized care they need.

For people with advanced ovarian cancer, surgery may take place before chemotherapy or after several cycles of treatment. A recent review found that neither approach is best for everyone. The most important goal is safely removing all visible cancer. Treatment timing should be based on the cancer’s location and extent, the patient’s overall health, and the surgical team’s expertise. Evaluation by an experienced gynecologic oncologist can help guide this complex decision.

Recovering from CRS/HIPEC can bring nutrition challenges that patients and caregivers may not expect. In interviews with 20 colorectal cancer survivors and 10 caregivers, researchers found that diarrhea, early fullness, pain, meal preparation, and changing dietary needs can complicate recovery. The study highlights the value of earlier, ongoing, and individualized nutrition support to help patients and caregivers feel better prepared for life after CRS/HIPEC.

A new study followed 111 patients with pseudomyxoma peritonei (PMP) for one year after cytoreductive surgery (CRS) and HIPEC. Quality of life declined most during the early weeks after surgery, with fatigue, pain, appetite loss, sleep difficulties, and other symptoms affecting recovery. Most measures improved steadily and returned to or approached pre-surgery levels within 6–12 months, offering patients and caregivers valuable insight into what recovery may look like.

A new study found that while CT scans provide a useful estimate of the extent of peritoneal metastases, they often underestimate the amount of cancer found during surgery. Diagnostic laparoscopy may offer a more accurate assessment in selected patients, helping physicians make more informed decisions about cytoreductive surgery.

A new multi-institutional study found that a second cytoreductive surgery (CRS) with or without HIPEC may be a safe option for carefully selected patients with recurrent colorectal cancer that has spread to the peritoneum. Patients who underwent repeat surgery had similar complication rates and lived longer than those treated with systemic therapy or supportive care alone.

A new study examined how often incisional hernias occur after cytoreductive surgery (CRS) and HIPEC for colorectal and appendiceal cancers. Researchers found that patients with a history of prior open abdominal surgery or a previous hernia had the highest risk, highlighting the importance of individualized surgical planning, recovery, and long-term follow-up.

PIPAC is a newer way to deliver chemotherapy directly to cancers that have spread to the lining of the abdomen. Using a minimally invasive procedure, chemotherapy is sprayed as a fine mist to improve drug delivery while reducing side effects. Learn how PIPAC works, who may benefit, how it differs from HIPEC, and why it is being studied in clinical trials.

A new feasibility study found that ultrasound-guided progressive pneumoperitoneum (PPP) allowed patients with "non-accessible" abdomens to safely receive PIPAC, a treatment for peritoneal carcinomatosis. While only five patients were studied, all successfully underwent PIPAC without major complications, suggesting this technique may expand treatment options for selected patients.

If your care team recommends chemotherapy before stomach cancer surgery, you may wonder whether it makes surgery riskier. This study found that patients who received chemotherapy before surgery had similar complication rates, hospital stays, and survival as those who had surgery first—and were even less likely to be readmitted to the hospital after surgery.

HIPEC has moved from controversy toward becoming an important treatment option for carefully selected patients with advanced ovarian cancer. This editorial reviews the growing evidence showing improved survival without added long-term quality-of-life concerns and highlights why treatment at experienced CRS/HIPEC centers is so important.

Being told your cancer is "inoperable" may not be the end of the story. New research shows that many patients who sought a second opinion at a specialized peritoneal cancer center were ultimately able to undergo successful surgery. Learn why expert evaluation can open the door to additional treatment options—and why a second opinion could make all the difference.

We're proud to introduce "Been There", a new community-sourced resource filled with tips from patients and practical wisdom from people who have walked through abdominal cancer themselves.

We're excited to introduce the Abdominal Cancers Webinar Recording Library. Facing abdominal cancers can be overwhelming. Access to clear, relevant, and compassionate information should not be.

In peritoneal oncology, helping patients and caregivers find support, community, and a voice is not extra. It is part of helping them live through the disease, the treatment, and what comes after. This approach introduces an unobtrusive way for clinicians to broaden and deepen the care and services offered to patients and caregivers through the connection to those organizations.

Peritoneal metastases are difficult to treat because standard IV chemotherapy often cannot reach tumors inside the abdomen effectively. This review explores NIPS, an approach that combines intravenous chemotherapy with repeated chemotherapy delivered directly into the abdominal cavity. Early research—especially in gastric cancer—suggests this strategy may improve disease control, increase eligibility for surgery, and help some patients live longer.

International experts are working to make treatment for advanced ovarian cancer more personalized. This special issue of PSOGI World News highlights new evidence supporting careful patient selection for cytoreductive surgery and HIPEC, the growing role of minimally invasive surgery, and how emerging technologies like artificial intelligence may improve treatment planning and outcomes in the future.

New ovarian cancer research presented at ASCO 2026 highlights promising advances in personalized treatment. In an interview with gynecologic oncologist Abdulrahman K. Sinno, MD, experts discuss emerging therapies and the continued importance of HIPEC for select patients with advanced disease, underscoring the value of exploring all available treatment options.

June is Uterine and Endometrial Cancers Awareness Month—a time to raise awareness, share knowledge, and support the thousands of individuals and families affected by these gynecologic cancers each year.